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Inflammation is one of the early phases in the development of gastric cancer. Therefore, several studies have examined the
association of polymorphisms in tumour-necrosis factor-A gene (TNF-A) with gastric cancer risk. This meta-analysis reviews and
summarises published evidence for these associations. Searching several databases yielded 24 independent studies that reported on
the associations between TNF-A polymorphisms and gastric cancer risk. We analysed available data for the most commonly
investigated polymorphisms: TNF-A –308G4A (23 studies), TNF-A –238G4A (9 studies), and TNF-A –857C4T (5 studies).
Summary odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated in the random-effects model using the
DerSimonian–Laird method. Q-statistic and I
2-statistic were calculated to examine heterogeneity, and funnel plots were plotted to
examine small study effects. The overall ORs (95% CIs) for AG and AA genotypes vs GG genotype for TNF-A –308 were 1.09 (0.94–
1.27) and 1.49 (1.11–1.99), respectively. For TNF-A –238, the corresponding ORs (95% CIs) were 1.05 (0.84–1.33) and 1.25 (0.30–
5.26), respectively. The overall ORs (95% CIs) for CT and TT genotypes (vs CC) for TNF-A –857 were 1.06 (0.89–1.27) and 1.57
(0.91–2.70), respectively. The statistically significant association between TNF-A –308GG and gastric cancer was limited to western
populations. This association showed little heterogeneity (I
2¼0) and remained consistently strong when analyses were limited to
anatomic and histologic subtypes of gastric cancer, or limited to studies in which genotype frequencies were in Hardy–Weinberg
equilibrium, or limited to larger studies. These same subgroup analyses did not change results associated with other polymorphisms.
In conclusion, TNF-A –308AA genotype was associated with a statistically significant increased risk of gastric cancer, whereas other
studied polymorphisms were not. The association between TNF-A –857TT genotype and gastric cancer was near significant, and may
become significant if more studies are published.
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Inflammation in the form of chronic superficial gastritis is one of
the early phases in the development of gastric cancer (Correa,
1992). Therefore, a stronger inflammatory response by the host
may modify gastric cancer risk. The first published epidemiologic
evidence for this hypothesis came from a study published in
Nature, which showed an increased risk of gastric cancer and its
precursor lesions associated with proinflammatory polymor-
phisms in interleukin-1B (IL-1B) and IL-1RN genes (El Omar
et al, 2000). Subsequent studies presented more data on the
associations between several proinflammatory polymorphisms and
gastric cancer. Some studies suggested that these polymorphisms
increase gastric cancer risk, and, in some studies, this increase in
risk was observed only in certain subgroups such as certain
anatomical subsites (ie, noncardia) (El Omar et al, 2003) or
histological subtypes (ie, intestinal type) (Machado et al, 2001) of
gastric cancer. Other studies, however, showed no association or
even inverse associations.
In addition to polymorphisms in interleukin genes, the
polymorphisms in the promoter region of tumour-necrosis
factor-A (TNF-A) gene have been extensively studied in relation
to gastric cancer. Three polymorphisms in TNF-A genes have been
studied more than the other polymorphisms. TNF-A –308G4A
is associated with an increased production of TNF-a (Jang
et al, 2001), which is a central mediator of the immune
response and shares many biologic properties with IL-1. The
function and significance of TNF-A  238G4A is less clear,
but because a putative repressor site is located in a 25-base
stretch that includes position  238, this polymorphism may be
functional (Jang et al, 2001). TNF-A  857C4T is also associated
with higher transcriptional activity of TNF-A (Hohjoh and
Tokunaga, 2001).
Since the previous results have been inconclusive regarding the
associations between TNF-A genotypes and gastric cancer risk,
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sthe purpose of this meta-analysis is to review studies that have
examined those polymorphisms. Where possible, we examine
these associations by anatomical or histological subtypes of gastric
cancer, and by Helicobacter pylori positivity.
METHODS
Selection of studies
We conducted a comprehensive search by examining several
databases for all papers that had been published on the association
between TNF-A polymorphisms and gastric cancer risk. All results
were updated on 15 October 2007. The following terms were used
in PubMed Databases search: (‘Interleukins’ [MeSH] OR ‘Tumor
Necrosis Factor-alpha’ [MeSH] OR (Tumor Necrosis) OR TNF)
AND (‘Stomach Neoplasms’ [MeSH] OR (gastric cancer) OR
(stomach cancer)) AND (‘Polymorphism, Genetic’ [MeSH] OR
polymorphism OR polymorphisms). The following terms were
used in ISI Database search: (TS¼(Interleukins) OR TS¼(Tumor
Necrosis Factor-alpha) OR TS¼(Tumor Necrosis) OR
TS¼(TNF)) AND (TS¼(Stomach Neoplasms) OR TS¼(gastric
cancer) OR TS¼(stomach cancer)) AND (TS¼(Polymorphism,
Genetic) OR TS¼(polymorphism) OR TS¼(polymorphisms)).
Other databases and search terms were MedCarib, LILACS,
IMEMR, IndMed, and PAHO databases, searched for (gastric OR
stomach) AND (cancer OR carcinoma OR neoplasms); IMSEAR
database, searched for combinations of gastric or stomach with
cancer or carcinoma or neoplasms; and J-EAST database, searched
for combinations of gastric or stomach with cancer or carcinoma
or neoplasms plus polymorphism. In addition, references of cited
articles were reviewed.
Two of the authors reviewed results of each of the database
searches to make sure that published papers are not missed. In
addition, where overall data were missing, we contacted the
authors for further information.
Using these approaches, reports on TNF-A polymorphisms in
relation to gastric cancer was found in a total of 29 articles (Jang
et al, 2001; Wu et al, 2002, 2003, 2004; El Omar et al, 2003; Garza-
Gonzalez et al, 2003, 2005; Machado et al, 2003; Fei et al, 2004; Glas
et al, 2004; Lee et al, 2004, 2005; Ohyama et al, 2004; Torres et al,
2004; Guo et al, 2005; Li et al, 2005; Lu et al, 2005; Perri et al, 2005;
Rocha et al, 2005; Zambon et al, 2005; Kamangar et al, 2006a;
Kim et al, 2006; Morgan et al, 2006; Shirai et al, 2006; Deans et al,
2007; Garcia-Gonzalez et al, 2007; Hou et al, 2007; Seno et al, 2007;
Sugimoto et al, 2007). Three studies (Garza-Gonzalez et al,
2003; Wu et al, 2003; Shirai et al, 2006) were excluded from the
analyses because their results were reported in other studies
(Ohyama et al, 2004; Wu et al, 2004; Garza-Gonzalez et al, 2005).
One more study was excluded because the results had been
reported for a combination of oesophageal and gastric cancers
(Deans et al, 2007). Another study (Seno et al, 2007) was excluded
because genotype frequencies were not reported. Therefore, a total
of 24 studies were used for calculating summary statistics.
Data extraction and statistical analysis
For TNF-A  308 (rs1800629) and TNF-A  238 (rs361525),
numbers and percentages of GG, GA, and AA genotypes, and for
TNF-A  857 (rs1799724), numbers and percentages of CC, CT, and
TT genotypes were extracted by case status. For GG and GA vs GG
genotypes (TNF-A  308 and  238) and for TT and TC vs CC
genotypes (TNF-A  857), odds ratios (ORs) and 95% confidence
intervals (95% CIs) were calculated. We performed similar
calculations for AA vs a combination of GA and GG genotypes
(TNF-A  308 and  238), and for TT vs a combination of TC and
CC genotypes (TNF-A  857) to examine the applicability of
recessive models. Likewise, we did similar analyses for a
combination of AA and GA vs GG genotypes (TNF-A  308 and
 238) and for combination of TT and TC vs CC genotypes (TNF-A
 857) to examine whether dominant models apply. We used both
random-effects models (DerSimonian–Laird method) and fixed-
effects models (Mantel–Haenszel method) to calculate overall
summary ORs and 95% CIs. Because these two methods yielded
similar results, we chose only random-effects models (Moayyedi,
2004) to present forest plots, and all other analyses described from
here onwards.
Some of the published studies found associations only with
certain anatomical subsites (ie, noncardia) or histological subtypes
(ie, intestinal type) of gastric cancer. Therefore, we calculated
summary ORs and 95% CIs for noncardia cancer, where genotype
data were presented by anatomical location, and for intestinal-type
cancer, where data on histology were available. We examined the
association between TNF-A  308 and gastric cancer in studies that
reported this association among H. pylori-positive subjects. It has
been suggested that proinflammatory polymorphisms in inter-
leukins may be associated with higher risk of gastric cancer in
western countries, but not in East Asian countries. Therefore,
study populations were classified as western (Europe and
Americas) vs East Asian (China, Korea, Taiwan, and Japan), and
subgroup analyses were performed for each group. In all, 12
studies were from western and 12 studies were from East Asian
countries.
We examined the effect of Hardy–Weinberg equilibrium (HWE)
on the results of our meta-analysis by calculating summary ORs
and 95% CIs for studies in which these alleles were in HWE among
controls. The strategy was to exclude studies in which genotypes
violated HWE at a¼0.05.
We plotted Begg’s funnel plot to examine small study effects
(Sterne et al, 2001). We also used the method of Begg and
Mazumdar (1994) to calculate P for rank correlation and Egger’s
weighted regression method (Egger et al, 1997) to calculate P for
bias. For sensitivity analysis, we excluded smaller studies and
recalculated the summary ORs (95% CIs) using only larger studies.
To examine result heterogeneity among studies, the Q-statistic
for homogeneity (using Mantel–Haenszel weights) and the
I
2-statistic (Higgins et al, 2003) were calculated. All analyses were
done using STATA software, version 9.2 (STATA Corporation,
College Station, TX, USA). Throughout the paper, two-sided
P-values o0.05 were considered as statistically significant.
RESULTS
Twenty-four studies with a total number of 4399 cases and 6855
controls were included in this analysis (Table 1). The most
commonly investigated genotypes were TNF-A  308,  238, and
 857, which were reported in 23, 9, and 5 studies, respectively.
Since other genotypes, such as TNF-A  1031, were investigated in
a very small number of studies, only data on the above mentioned
three genotypes were analysed. Most studies used healthy
volunteers or blood donors as control subjects. The frequency of
TNF-A  308A and TNF-A  238A alleles ranged from 0.9 to 16.2%
and from 1.2 to 10.3%, respectively. The frequency of TNF-A
 857T allele ranged from 14.3 to 19.6%. Median frequencies of
TNF-A  308A allele were 12.5 and 6.8% in western populations
and East Asian populations, respectively. Corresponding frequen-
cies for TNF-A  238A allele were 4.9 and 3.8%, and for TNF-A
 857T allele were 19.6 and 15.0%, respectively.
TNF-A  308
Study-specific and summary ORs (95% CIs) are shown in
Figure 1A. For all gastric cancers, the random-effect overall ORs
(95% CIs) associated with heterozygous (GA vs GG) and
homozygous (AA vs GG) proinflammatory genotypes were 1.09
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First
author Study location Year
a
Number of
cases/controls
Source of control
selection
%  308A allele
frequency
b
%  238A allele
frequency
c
%  857T allele
frequency
d
P, HWE
 308
e
P, HWE
 238
f
P, HWE
 857
g
1 Jang Korea (E) 2001 52/92 Healthy volunteers 3.8 7.1 — 0.70 0.39 —
2 Wu Taiwan (E) 2002 150/220 Healthy volunteers 12.0 1.8 — o0.01 o0.01 —
3 El-Omar USA (W) 2003 314/210 Population based 15.2 — — 0.55 — —
4 Machado Portugal (W) 2003 287/304 Healthy volunteers 12.7 — — 0.65 — —
5 Fei China (E) 2004 56/164 Healthy volunteers 6.7 — — 0.12 — —
6 Glas Germany (W) 2004 88/145 Healthy volunteers 15.2 3.8 — 0.67 0.63 —
7 Lee SG Korea (E) 2004 341/261 Healthy volunteers 8.4 4.8 15.9 0.49 0.42 0.85
8 Torres Colombia (W) 2004 44/66 Clinic based 7.6 — — 0.51 — —
9 Wu Taiwan (E) 2004 204/210 Healthy volunteers 12.4 1.7 14.3 o0.01 o0.01 0.20
10 Ohayama Japan (E) 2004 300/472 Clinic based — — 18.6 — — 0.90
11 Garza-Gonzalez Mexico (W) 2005 63/215 Clinic based 8.6 — — 0.61 — —
12 Guo China (E) 2005 264/437 Healthy volunteers 5.9 — — o0.01 — —
13 Lee JY Korea (E) 2005 122/120 Healthy volunteers 7.1 — — 0.40 — —
14 Li China (E) 2005 59/264 Healthy volunteers 7.2 — — 0.56 — —
15 Lu China (E) 2005 250/300 Population based 4.7 3.8 — 0.08 0.49 —
16 Perri Italy (W) 2005 184/362 Healthy volunteers 10.9 — — 0.15 — —
17 Rocha Brazil (W) 2005 161/535 Healthy volunteers 13.9 — — 0.34 — —
18 Zambon Italy (W) 2005 129/644 Clinic based 12.3 5.9 19.6 0.90 0.38 o0.01
19 Kamangar Finland (W) 2006 112/208 Healthy cohort subjects 13.5 1.2 — 0.29 0.86 —
20 Kim Korea (E) 2006 237/461 Healthy volunteers 6.8 — — 0.91 — —
21 Morgan Honduras (W) 2006 168/161 Population based 3.7 — — 0.62 — —
22 Hou Poland (W) 2007 305/427 Population based 16.2 — — 0.19 — —
23 Sugimoto Japan (E) 2007 105/172 Clinic based 0.9 — 15.7 0.91 — 0.11
24 Garcia-Gonzalez Spain (W) 2007 404/404 Healthy volunteers 11.3 10.3 — 0.35 0.01 —
E¼East Asian country; HWE¼Hardy–Weinberg equilibrium; TNF-A¼tumour-necrosis factor-A; W¼western country.
aYear: Publication year.
bPercentage of TNF-A –308A allele frequency among controls.
cPercentage of TNF-A
–238 A allele frequency among controls.
dPercentage of TNF-A –857 T allele frequency among controls.
eP-value for HWE for TNF-A –308 polymorphism among controls.
fP-value for HWE for TNF-A –238 polymorphism among
controls.
gP-value for HWE for TNF-A –857 polymorphism among controls.
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Genetics and Genomics(0.94–1.27) and 1.49 (1.11–1.99), respectively, and the corre-
sponding fixed-effect ORs (95% CIs) were 1.14 (1.02–1.27) and
1.51 (1.14–1.99), respectively. Recessive model was the best-fitting
inheritance model for TNF-A  308. However, because GG
genotype was much more frequent than GA and AA genotypes,
comparing GAþGG vs AA genotype did not have a material effect
on the test power. Therefore, the results are reported separately for
GA vs GG and AA vs GG genotypes.
Table 2 summarises overall and subgroup-specific summary
ORs and 95% CIs. Only a fraction of studies presented data on
subgroups. For example, only 6 out of the 23 studies reported their
results by intestinal vs diffuse histology types. Among these,
summary ORs (95% CIs) for GA vs GG and AA vs GG genotypes
were 1.17 (0.85–1.59) and 2.88 (1.74–4.77) for noncardia cancers
and 0.98 (0.68–1.40) and 2.17 (1.17–4.03) for intestinal-type
gastric cancers, respectively. When we limited our analysis to H.
pylori-positive cases and controls, these ORs (95% CIs) were 0.66
(0.33–1.30) and 3.23 (0.10–99.4), respectively. The summary ORs
(95% CIs) for GA vs GG and AA vs GG genotypes were 1.14 (0.95–
1.37) and 1.74 (1.21–2.51) for western countries, and 1.02 (0.78–
1.34) and 1.14 (0.70–1.84) for eastern countries, respectively.
In three studies, the distributions of TNF-A  308 genotypes
among controls were not in HWE (Table 1). Limiting the analysis
to the studies with HWE, the summary ORs (95% CIs) for GA vs
GG and AA vs GG genotypes were 1.08 (0.91–1.28) and 1.73 (1.22–
2.44), respectively.
Figure 1B shows Begg’s funnel plot for the association between
TNF-A  308 and gastric cancer. This figure shows logarithm of OR
(Y axis) vs its standard error (SE) (X axis). Smaller studies have
larger SEs, therefore points showing these studies are in the right-
hand side of the graph. For GA vs GG genotypes, there was
evidence for bias using Egger’s weighted regression method (P for
bias¼0.03) and using the method of Begg and Mazumdar
(P¼0.07). There was no evidence of bias for AA vs GG genotypes
using either Egger’s method (P for bias¼0.44) or Begg’s method
(P¼0.87). We excluded small studies, defined as those having an
SE40.5. After these exclusion, the summary OR (95% CI) changed
to 1.13 (0.97–1.32) for GA vs GG, and 1.68 (1.08–2.61) for AA vs
GG.
Table 2 shows the Q- and I
2-statistics for the overall and
subgroup analyses. For the overall analysis, the Q-statistic was
significant (P¼0.02) and I
2 (34%) showed a moderate variation
for GA vs GG genotypes. For AA vs GG genotypes, the Q-statistic
was not significant (P¼0.74) and I
2 was equal to zero. Subgroup
analyses showed similar patterns as overall analyses. While for
most subgroup analyses, the P-value for GA vs GG genotypes was
significant or remained close to significance level and I
2 showed
moderate heterogeneity among studies, P for heterogeneity was not
significant for AA vs GG genotypes (Table 2).
TNF-A  238
Figure 2A summarises the ORs and 95% CIs for the associations
between TNF-A  238A carrying genotypes and gastric cancer risk.
For all gastric cancers, the random-effect overall ORs (95% CIs)
were 1.05 (0.84–1.33) for GA vs GG genotypes and 1.25 (0.30–5.26)
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Figure 1 The association between TNF-A  308 and gastric cancer (GA and AA genotypes vs GG). (A) Forest plot – studies are sorted in order of
publication year. (B) Begg’s funnel plots for the associations.
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sTable 2 Overall and group-specific summary statistics for TNF-A  308, TNF-A  238, and TNF-A  857 and gastric cancer
Number of studies Polymorphisms Q-statistic
a P-value
b I
2 (%)
c Random-effect OR (95% CI) Fixed-effect OR (95% CI)
TNF-A –308 (4099/6383)
d
All gastric cancers 23 GA vs GG 36.43 0.03 40 1.09 (0.94–1.27) 1.14 (1.02–1.27)
19
e AA vs GG 13.77 0.74 0 1.49 (1.11–1.99) 1.51 (1.14–1.99)
Noncardia cancers 6 GA vs GG 11.80 0.04 58 1.17 (0.85–1.59) 1.23 (1.02–1.49)
6A A vs GG 4.18 0.52 0 2.88 (1.74–4.77) 2.97 (1.83–4.84)
Intestinal-type cancers 6 GA vs GG 11.68 0.04 57 0.98 (0.68–1.40) 1.03 (0.83–1.29)
6A A vs GG 4.08 0.44 0 2.17 (1.17–4.03) 2.00 (1.11–3.61)
Helicobacter pylori-positive subjects 3 GA vs GG 4.03 0.13 50 0.66 (0.33–1.30) 0.77 (0.51–1.15)
2
e AA vs GG 2.63 0.11 62 3.23 (0.10–99.84) 4.05 (0.91–18.04)
Western populations 12 GA vs GG 18.37 0.07 40 1.14 (0.95–1.37) 1.19 (1.04–1.36)
10
e AA vs GG 6.53 0.69 0 1.74 (1.21–2.51) 1.76 (1.24–2.50)
East Asian population 11 GA vs GG 16.80 0.08 40 1.02 (0.78–1.34) 1.03 (0.85–1.25)
9
e AA vs GG 5.36 0.72 0 1.14 (0.70–1.84) 1.15 (0.72–1.83)
Studies in HWE 20 GA vs GG 33.83 0.02 44 1.08 (0.91–1.28) 1.14 (1.01–1.28)
16
e AA vs GG 11.28 0.73 0 1.73 (1.22–2.44) 1.73 (1.25–2.41)
TNF-A –238 (1730/2484)
d
All gastric cancers 9 GA vs GG 6.87 0.55 0 1.05 (0.84–1.33) 1.04 (0.83–1.31)
6
e AA vs GG 11.12 0.05 55 1.25 (0.30–5.26) 0.87 (0.41–1.87)
Noncardia cancers 3 GA vs GG 2.39 0.30 16 1.04 (0.71–1.52) 1.01 (0.74–1.40)
2
e AA vs GG 9.49 o0.01 89 1.38 (0.01–157.0) 0.72 (0.24–2.09)
Intestinal-type cancers 3 GA vs GG 1.80 0.41 0 1.40 (0.93–2.10) 1.39 (0.93–2.08)
2
e AA vs GG 0.00 — 0 0.13 (0.01–2.20) 0.13 (0.01–2.20)
H. pylori-positive subjects 0 — — — — — —
Western populations 4 GA vs GG 2.33 0.51 0 1.05 (0.78–1.41) 1.05 (0.78–1.41)
2
e AA vs GG 10.25 o0.01 90 1.25 (0.01–171.9) 0.64 (0.22–1.85)
East Asian populations 5 GA vs GG 4.54 0.34 12 1.04 (0.69–1.58) 1.03 (0.72–1.47)
4
e AA vs GG 0.79 0.85 0 1.28 (0.39–4.21) 1.30 (0.41–4.06)
Studies in HWE 6 GA vs GG 6.53 0.26 23 1.08 (0.75–1.55) 1.06 (0.78–1.42)
3
e AA vs GG 2.85 0.24 30 4.04 (0.57–28.8) 3.79 (0.93–15.40)
TNF-A –857 (1079/1759)
d
All gastric cancers 5 CT vs CC 1.24 0.87 0 1.06 (0.89–1.27) 1.06 (0.89–1.27)
5T T vs CC 5.06 0.28 21 1.57 (0.91–2.70) 1.54 (0.98–2.43)
Noncardia cancers 1 CT vs CC 0.00 — 0 0.94 (0.63–1.41) 0.94 (0.63–1.41)
1T T vs CC 0.00 — 0 0.75 (0.17–3.38) 0.74 (0.17–3.38)
Intestinal-type cancers 0 — — — — — —
H. pylori-positive subjects 0 — — — — — —
Western populations 1 CT vs CC 0.00 — 0 0.94 (0.63–1.41) 0.94 (0.63–1.41)
1T T vs CC 0.00 — 0 0.75 (0.17–3.38) 0.75 (0.17–3.38)
East Asian populations 4 CT vs CC 0.81 0.85 0 1.09 (0.90–1.33) 1.09 (0.90–1.33)
4T T vs CC 4.07 0.25 26 1.73 (0.95–3.14) 1.68 (1.04–2.72)
Studies in HWE 4 CT vs CC 0.81 0.85 0 1.09 (0.90–1.33) 1.09 (0.90–1.33)
4T T vs CC 4.07 0.25 26 1.73 (0.95–3.14) 1.68 (1.04–2.72)
CI¼confidence interval; HWE¼Hardy–Weinberg equilibrium; OR¼odds ratio; TNF-A¼tumour-necrosis factor-A.
aw
2 Q-statistic for homogeneity in random-effect model.
bP-value for the Q-statistic in random-effect model.
cHiggins’ I
2-statistic for heterogeneity in random-effect model.
dNumber of cases/number of controls.
eSome studies were excluded because of the null values for AA genotype frequency among both cases and controls.
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Genetics and Genomicsfor AA vs GG genotypes. The fixed-effect ORs (95% CIs) were 1.04
(0.83–1.31) and 0.87 (0.41–1.87), respectively. When we investi-
gated the inheritance models, TNF-A  238 showed neither
recessive nor dominant models (data not shown). Therefore, the
results are reported separately as GA vs GG and AA vs GG
genotypes.
For noncardia cancers, the ORs (95% CIs) were 1.04 (0.71–1.52)
for GA genotype and 1.38 (0.01–157.0) for AA genotype. Limiting
the results to intestinal-type cancers, the ORs (95% CIs) were 1.40
(0.93–2.10) for GA genotype and 0.13 (0.01–2.20) for AA
genotype. For this last comparison, one of the three studies was
excluded because of the null values for AA genotype frequency
among both cases and controls. For studies from western
countries, summary ORs (95% CIs) for GA and AA genotypes
were 1.05 (0.78–1.41) and 1.25 (0.01–171.9), respectively. For the
studies from East Asian countries, these corresponding ORs (95%
CIs) were 1.04 (0.69–1.58) and 1.28 (0.39–4.21), respectively.
In three studies, TNF-A  238 genotype in control subjects were
not in HWE (Table 1). After excluding these three studies, the
summary ORs (95% CIs) for GA and AA genotypes were 1.08
(0.75–1.55) and 4.04 (0.57–28.8), respectively.
Begg’s funnel plot for the association between TNF-A  238 and
gastric cancer is shown in Figure 2B. For both GA vs GG and AA vs
GG genotypes, there was no evidence for bias using either the
method of Begg and Mazumdar (P for rank correlation¼1.00 and
0.85, respectively) or Egger’s weighted regression method (P for
bias¼0.84 and 0.75, respectively). For GA genotype, after
excluding studies with an SE40.5, the summary OR (95% CI)
was 1.04 (0.82–1.33). For AA genotype, all of the studies had an
SE40.5.
For GA genotype, the Q-statistic was nonsignificant for the
overall association (P¼0.55) and subgroup analyses, and
I
2-statistic showed little heterogeneity among studies (Table 2).
For AA genotype, the Q-statistic was significant for the overall
association (P¼0.05) and also for noncardia, intestinal-type, and
western populations subgroups, where I
2-statistic showed moder-
ate-to-high heterogeneity.
TNF-A  857
Figure 3A summarises the ORs and 95% CIs for the associations
between TNF-A  857T carrying genotypes (TC and TT vs CC) and
gastric cancer risk. For all gastric cancers, the random-effect
overall ORs (95% CIs) for TC vs CC and TT vs CC genotypes were
1.06 (0.89–1.27) and 1.57 (0.91–2.70), respectively. The fixed-
effect ORs (95% CIs) were 1.06 (0.89–1.27) and 1.54 (0.98–2.43),
respectively. Like TNF-A  238, TNF-A  857 showed neither
recessive nor dominant model. Therefore, the results are reported
separately for TC vs CC and TT vs CC genotypes.
Only one study reported the associations between TNF-A  857
and noncardia cancers. This study was also the only study from
western countries; the ORs (95% CIs) for TC and TT genotypes in
this study were 0.94 (0.63–1.41) and 0.75 (0.17–3.38), respectively.
For studies from eastern countries, summary ORs (95% CIs) for
TC and TT genotypes were 1.09 (0.90–1.33) and 1.73 (0.95–3.14),
respectively.
In one study, TNF-A  857 genotypes among controls were not
in HWE (Table 1). After excluding that study, the summary ORs
(95% CIs) for TC and TT genotypes were 1.09 (0.90–1.33) and 1.73
(0.95–3.14), respectively.
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Figure 2 The association between TNF-A  238 and gastric cancer (GA and AA genotypes vs GG). (A) Forest plot – studies are sorted in order of
publication year. (B) Begg’s funnel plots for the associations.
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gastric cancer is shown in Figure 3B. For both TC and CC
genotypes, there was no evidence for bias using either the method
of Begg and Mazumdar (P for rank correlation¼0.81 and 0.46,
respectively) or Egger’s weighted regression method (P for
bias¼0.87 and 0.89, respectively). For TC vs CC genotypes, none
of the studies had an SE40.5. For TT vs CC genotypes, after
excluding two studies with SEs40.5, the summary OR (95% CI)
changed to 1.66 (0.81–3.42).
The Q-statistic was nonsignificant for the overall associations
and also for the subgroup analyses. Furthermore, I
2-statistic
showed little to moderate heterogeneity among studies (Table 2).
DISCUSSION
Gastric cancer is the second most common cause of cancer death
in the world (Parkin et al, 2005; Kamangar et al, 2006c). Because
inflammation is one of the initial phases of gastric carcinogenesis,
especially for intestinal-type gastric cancer (Correa, 1992),
inflammation-related polymorphisms, including single-nucleotide
polymorphisms (SNPs) in TNF-A gene, have been extensively
studied in relation to gastric cancer (Camargo et al, 2006). The
most extensively studied of these proinflammatory polymorphisms
are two linked SNPs in IL-1B ( 511C4T and  31T4C) and a
penta-allelic variable number tandem-repeat polymorphism and
allele 2 (IL-1RN*2). So far, at least three meta-analyses of the
associations between these polymorphisms and gastric cancer risk
have been published (Camargo et al, 2006; Kamangar et al, 2006b;
Wang et al, 2007). However, to our knowledge, no systematic
review has been previously published on the association between
TNF-A SNPs and gastric cancer. Of the three polymorphisms
reviewed in this report, –308G4A is studied more extensively and
a biologic role for it has been identified.
An analysis of the 23 studies that presented results on TNF-A
 308G4A showed no association between GA genotype (vs GG)
and gastric cancer risk. However, there was a statistically
significant increased risk associated with AA genotype using both
fixed-effects and random-effects models. This association was
limited to studies from western countries, and no association was
found in studies from East Asian countries. Previous studies have
suggested that frequencies of genetic markers often shows high
variations among various ethnic and racial groups (Garte et al,
2001; Ioannidis et al, 2004), whereas differences in genetic effects
(in terms of ORs) are much less common (Ioannidis et al, 2004).
This meta-analysis found that the median prevalence of TNF-A
 308A carrier genotypes was almost twice as high in western as in
East Asian populations (23.5 vs 13.4%). However, unlike what has
been shown for most previous associations (Ioannidis et al, 2004),
the OR associated with AA genotype showed a difference between
western and East Asian studies. We cannot explain the reasons for
this latter observed difference.
No SNPs have been consistently associated with gastric cancer
risk (Gonzalez et al, 2002). Indeed, because several initially
promising gene–disease associations gravitated towards null over
time (Ioannidis et al, 2001; Kamangar et al, 2006b), it has been
suggested that journals should take a cautious approach in
publishing such associations (Ioannidis, 2006). However, as shown
in the results and discussed below, within the studies from western
countries, the association between TNF-A  308AA genotype and
gastric cancer risk seems robust to many tests, including testing
for publication bias, heterogeneity, and HWE. Interestingly, a
study within the InterLymph Consortium found that this same
polymorphism was consistently associated with an increased risk
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Figure 3 The association between TNF-A  857 and gastric cancer (TC and TT genotypes vs CC). (A) Forest plot – studies are sorted in order of
publication year. (B) Begg’s funnel plots for the associations.
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sof diffuse large B-cell lymphoma with a comparable magnitude of
association (Rothman et al, 2006); the ORs associated with GA and
AA genotypes (vs GG genotype) were 1.29 and 1.65, respectively.
The studies that participated in this Consortium were all from
western countries.
The forest plots for TNF-A  308AA genotype did not suggest a
dominant effect for any single study. We used funnel plots and two
formal statistical methods (Egger’s weighted regression method
and the rank correlation method of Begg and Mazumdar) to detect
bias. In general, smaller studies, that is, those with higher SEs, had
lower ORs, and there was some evidence for publication bias using
both formal methods. However, excluding smaller studies did not
materially change the results. In 20 out of 23 studies, distribution
of TNF-A  308 among controls was in HWE. Limiting the analyses
to these 20 studies, the results remained essentially unchanged.
The overall heterogeneity between the studies was very low, as
indicated by the I
2 value of zero.
Since subgroup analyses are often limited by selective reporting
of significant subgroup results, such analyses generally need to be
interpreted with caution. However, in this report, limiting the
results of TNF-A  308 polymorphism to noncardia gastric cancers
or intestinal-type cancers made little difference. The summary ORs
for the AG genotype remained close to null and were nonsigni-
ficant, whereas those for the GG genotype remained statistically
significantly above one.
We found nine studies that examined the association between
TNF-A  238G4A polymorphism and gastric cancer risk. Unlike
that for TNF-A  308G4A polymorphism, a clear biologic role for
this polymorphism has not been found (Jang et al, 2001). There
was no association between gastric cancer risk and either the GA
or the AA genotypes using either random-effects or fixed-effects
models. Examining the data by anatomic and histologic subtypes
did not make a difference. No statistically significant association
was found when data were limited to East Asian populations,
western populations, studies with larger sample sizes, or studies in
which genotype frequencies were in HWE.
We found only five studies that had examined the association
between TNF-A  857C4T polymorphisms and gastric cancer. No
evidence was found for the association between CT (vs CC)
genotype and gastric cancer. Almost all studies showed null
associations, and there was little evidence for heterogeneity. The
overall association with the TT genotype, however, was near
significant. The overall pattern and magnitude of association is
similar to that found for TNF-A  308G4A polymorphism, but
further studies are needed to examine whether gastric cancer is
significantly associated with this polymorphism. The studies
showed some heterogeneity, with three showing strong positive
associations, one showing no association, and one showing an
inverse association. We believe that the currently available data do
not provide conclusive evidence for the presence of an association,
or lack thereof, between TNF-A  857TT genotype and gastric
cancer.
Inappropriate selection of controls is a major source of bias in
case–control studies. However, control groups for most of the
studies used in this meta-analysis were selected from among
healthy volunteers or blood donors, and TNF-A polymorphisms
are unlikely to be associated with these conditions. Because TNF
locus is on chromosome 6 (and not sex chromosomes), the
distribution of this polymorphism is not associated with sex.
Therefore, in theory, matching for sex should not affect the results.
Strengths of this meta-analysis are including 24 published
studies with a large number of cases and controls, presenting data
on several relevant methodologic aspects of these studies,
subgroup analyses according to predefined criteria, and using
other methods to examine the robustness of the summary
statistics. We acknowledge that this meta-analysis also has
limitations. Combining observational studies conducted in differ-
ent populations with various qualities of design to obtain summary
ORs and 95% CIs can sometimes be misleading (Shapiro, 1994),
and summary statistics need to be interpreted with caution (Egger
et al, 1998). However, as mentioned above, there is little evidence
for improper selection of control groups or for associations within
specific subgroups.
In summary, this systematic review found that TNF-A  308AA
genotype was moderately associated with an increased risk of
gastric cancer. TNF-A –308AG, TNF-A  238AA or AG, and TNF-A
 857CT or TT were not statistically significantly associated with
gastric cancer risk. It is possible that, with increasing the number
of studies, TNF-A  857TT may also be associated with an
increased risk of gastric cancer.
ACKNOWLEDGEMENTS
This research was supported in part by the Intramural Research
Program of the National Institutes of Health, National Cancer
Institute.
REFERENCES
Begg CB, Mazumdar M (1994) Operating characteristics of a rank
correlation test for publication bias. Biometrics 50: 1088–1101
Camargo MC, Mera R, Correa P, Peek Jr RM, Fontham ET, Goodman KJ,
Piazuelo MB, Sicinschi L, Zabaleta J, Schneider BG (2006) Interleukin-1beta
and interleukin-1 receptor antagonist gene polymorphisms and gastric
cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 1674–1687
Correa P (1992) Human gastric carcinogenesis: a multistep and multi-
factorial process – First American Cancer Society Award Lecture on
Cancer Epidemiology and Prevention. Cancer Res 52: 6735–6740
Deans C, Rose-Zerilli M, Wigmore S, Ross J, Howell M, Jackson A, Grimble
R, Fearon K (2007) Host cytokine genotype is related to adverse
prognosis and systemic inflammation in gastro-oesophageal cancer. Ann
Surg Oncol 14: 329–339
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis
detected by a simple, graphical test. BMJ 315: 629–634
Egger M, Schneider M, Davey SG (1998) Spurious precision? Meta-analysis
of observational studies. BMJ 316: 140–144
El Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA,
Herrera J, Lissowska J, Yuan CC, Rothman N, Lanyon G, Martin M,
Fraumeni Jr JF, Rabkin CS (2000) Interleukin-1 polymorphisms
associated with increased risk of gastric cancer. Nature 404: 398–402
El Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA,
Schoenberg JB, Stanford JL, Mayne ST, Goedert J, Blot WJ, Fraumeni
Jr JF, Chow WH (2003) Increased risk of noncardia gastric cancer
associated with proinflammatory cytokine gene polymorphisms. Gastro-
enterology 124: 1193–1201
Fei BY, Xia B, Deng CS, Xia XQ, Xie M, Crusius JB, Pena AS (2004)
Association of tumor necrosis factor genetic polymorphism with chronic
atrophic gastritis and gastric adenocarcinoma in Chinese Han popula-
tion. World J Gastroenterol 10: 1256–1261
Garcia-Gonzalez MA, Lanas A, Quintero E, Nicolas D, Parra-Blanco A,
Strunk M, Benito R, Angel SM, Santolaria S, Sopena F, Piazuelo E,
Jimenez P, Pascual C, Mas E, Irun P, Espinel J, Campo R, Manzano M,
Geijo F, Pellise M, Gonzalez-Huix F, Nieto M, Espinos J, Tito L, Bujanda
L, Zaballa M (2007) Gastric cancer susceptibility is not linked to pro- and
anti-inflammatory cytokine gene polymorphisms in whites: a nationwide
multicenter study in Spain. Am J Gastroenterol 102: 1878–1892
Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL,
Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar
K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell’Omo
M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A,
Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara
TNF polymorphisms and gastric cancer
F Gorouhi et al
1450
British Journal of Cancer (2008) 98(8), 1443–1451 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
sM, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van
Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart
V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A,
Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J,
Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker
I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E (2001) Metabolic
gene polymorphism frequencies in control populations. Cancer Epide-
miol Biomarkers Prev 10: 1239–1248
Garza-Gonzalez E, Bosques-Padilla FJ, El Omar E, Hold G, Tijerina-
Menchaca R, Maldonado-Garza HJ, Perez-Perez GI (2005) Role of the
polymorphic IL-1B, IL-1RN and TNF-A genes in distal gastric cancer in
Mexico. Int J Cancer 114: 237–241
Garza-Gonzalez E, Hold G, Perez-Perez GI, Bosques-Padilla FJ, Tijerina-
Menchaca R, Maldonado-Garza HJ, El Omar E (2003) Role of
polymorphism of certain cytokines in gastric cancer in Mexico.
Preliminary results. Rev Gastroenterol Mex 68: 107–112
Glas J, Torok HP, Schneider A, Brunnler G, Kopp R, Albert ED, Stolte M,
Folwaczny C (2004) Allele 2 of the interleukin-1 receptor antagonist gene
is associated with early gastric cancer. J Clin Oncol 22: 4746–4752
Gonzalez CA, Sala N, Capella G (2002) Genetic susceptibility and gastric
cancer risk. Int J Cancer 100: 249–260
Guo W, Wang N, Li Y, Zhang JH (2005) Polymorphisms in tumor necrosis
factor genes and susceptibility to esophageal squamous cell carcinoma
and gastric cardiac adenocarcinoma in a population of high incidence
region of North China. Chin Med J (Engl) 118: 1870–1878
Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring
inconsistency in meta-analyses. BMJ 327: 557–560
Hohjoh H, Tokunaga K (2001) Allele-specific binding of the ubiquitous
transcription factor OCT-1 to the functional single nucleotide poly-
morphism (SNP) sites in the tumor necrosis factor-alpha gene (TNFA)
promoter. Genes Immun 2: 105–109
Hou L, El Omar EM, Chen J, Grillo P, Rabkin CS, Baccarelli A, Yeager M,
Chanock SJ, Zatonski W, Sobin LH, Lissowska J, Fraumeni Jr JF, Chow
WH (2007) Polymorphisms in Th1-type cell-mediated response genes
and risk of gastric cancer. Carcinogenesis 28: 118–123
Ioannidis JP (2006) Journals should publish all ‘null’ results and should
sparingly publish ‘positive’ results. Cancer Epidemiol Biomarkers Prev 15: 186
Ioannidis JP, Ntzani EE, Trikalinos TA (2004) ‘Racial’ differences in genetic
effects for complex diseases. Nat Genet 36: 1312–1318
Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG (2001)
Replication validity of genetic association studies. Nat Genet 29: 306–309
Jang WH, Yang YI, Yea SS, Lee YJ, Chun JH, Kim HI, Kim MS, Paik KH
(2001) The  238 tumor necrosis factor-alpha promoter polymorphism is
associated with decreased susceptibility to cancers. Cancer Lett 166: 41–46
Kamangar F, Abnet CC, Hutchinson AA, Newschaffer CJ, Helzlsouer K,
Shugart YY, Pietinen P, Dawsey SM, Albanes D, Virtamo J, Taylor PR
(2006a) Polymorphisms in inflammation-related genes and risk of gastric
cancer (Finland). Cancer Causes Control 17: 117–125
Kamangar F, Cheng C, Abnet CC, Rabkin CS (2006b) Interleukin-1B
polymorphisms and gastric cancer risk – a meta-analysis. Cancer
Epidemiol Biomarkers Prev 15: 1920–1928
Kamangar F, Dores GM, Anderson WF (2006c) Patterns of cancer
incidence, mortality, and prevalence across five continents: defining
priorities to reduce cancer disparities in different geographic regions of
the world. J Clin Oncol 24: 2137–2150
Kim N, Cho SI, Yim JY, Kim JM, Lee DH, Park JH, Kim JS, Jung HC, Song IS
(2006) The effects of genetic polymorphisms of IL-1 and TNF-A on
Helicobacter pylori-induced gastroduodenal diseases in Korea. Helico-
bacter 11: 105–112
Lee JY, Kim HY, Kim KH, Kim SM, Jang MK, Park JY, Lee JH, Kim JH, Yoo
JY (2005) Association of polymorphism of IL-10 and TNF-A genes with
gastric cancer in Korea. Cancer Lett 225: 207–214
Lee SG, Kim B, Yook JH, Oh ST, Lee I, Song K (2004) TNF/LTA
polymorphisms and risk for gastric cancer/duodenal ulcer in the Korean
population. Cytokine 28: 75–82
Li C, Xia B, Yang Y, Li J, Xia HH (2005) TNF gene polymorphisms and
Helicobacter pylori infection in gastric carcinogenesis in Chinese
population. Am J Gastroenterol 100: 290–294
Lu W, Pan K, Zhang L, Lin D, Miao X, You W (2005) Genetic
polymorphisms of interleukin (IL)-1B, IL-1RN, IL-8, IL-10 and tumor
necrosis factor {alpha} and risk of gastric cancer in a Chinese population.
Carcinogenesis 26: 631–636
Machado JC, Figueiredo C, Canedo P, Pharoah P, Carvalho R, Nabais S,
Castro AC, Campos ML, Van Doorn LJ, Caldas C, Seruca R, Carneiro F,
Sobrinho-Simoes M (2003) A proinflammatory genetic profile increases
the risk for chronic atrophic gastritis and gastric carcinoma. Gastro-
enterology 125: 364–371
Machado JC, Pharoah P, Sousa S, Carvalho R, Oliveira C, Figueiredo C,
Amorim A, Seruca R, Caldas C, Carneiro F, Sobrinho-Simoes M (2001)
Interleukin 1B and interleukin 1RN polymorphisms are associated with
increased risk of gastric carcinoma. Gastroenterology 121: 823–829
Moayyedi P (2004) Meta-analysis: can we mix apples and oranges? Am J
Gastroenterol 99: 2297–2301
Morgan DR, Dominguez RL, Keku TO, Heidt PE, Martin CF, Galanko JA,
Omofoye OA, Sandler RS (2006) Gastric cancer and the high combina-
tion prevalence of host cytokine genotypes and Helicobacter pylori in
Honduras. Clin Gastroenterol Hepatol 4: 1103–1111
Ohyama I, Ohmiya N, Niwa Y, Shirai K, Taguchi A, Itoh A, Hirooka Y,
Wakai K, Hamajima N, Mori N, Goto H (2004) The association between
tumour necrosis factor-alpha gene polymorphism and the susceptibility
to rugal hyperplastic gastritis and gastric carcinoma. Eur J Gastroenterol
Hepatol 16: 693–700
Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002.
CA Cancer J Clin 55: 74–108
Perri F, Piepoli A, Bonvicini C, Gentile A, Quitadamo M, Di Candia M,
Cotugno R, Cattaneo F, Zagari MR, Ricciardiello L, Gennarelli M, Bazzoli
F, Ranzani GN, Andriulli A (2005) Cytokine gene polymorphisms in
gastric cancer patients from two Italian areas at high and low cancer
prevalence. Cytokine 30: 293–302
Rocha GA, Guerra JB, Rocha AM, Saraiva IE, da Silva DA, de Oliveira CA,
Queiroz DM (2005) IL1RN polymorphic gene and cagA-positive status
independently increase the risk of noncardia gastric carcinoma. Int J
Cancer 115: 678–683
Rothman N, Skibola CF, Wang SS, Morgan G, Lan Q, Smith MT, Spinelli JJ,
Willett E, De Sanjose S, Cocco P, Berndt SI, Brennan P, Brooks-Wilson A,
Wacholder S, Becker N, Hartge P, Zheng T, Roman E, Holly EA, Boffetta
P, Armstrong B, Cozen W, Linet M, Bosch FX, Ennas MG, Holford TR,
Gallagher RP, Rollinson S, Bracci PM, Cerhan JR, Whitby D, Moore PS,
Leaderer B, Lai A, Spink C, Davis S, Bosch R, Scarpa A, Zhang Y,
Severson RK, Yeager M, Chanock S, Nieters A (2006) Genetic variation in
TNF and IL10 and risk of non-Hodgkin lymphoma: a report from the
InterLymph Consortium. Lancet Oncol 7: 27–38
Seno H, Satoh K, Tsuji S, Shiratsuchi T, Harada Y, Hamajima N, Sugano K,
Kawano S, Chiba T (2007) Novel interleukin-4 and interleukin-1 receptor
antagonist gene variations associated with non-cardia gastric cancer in
Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine
genes. J Gastroenterol Hepatol 22: 729–737
Shapiro S (1994) Meta-analysis/Shmeta-analysis. Am J Epidemiol 140: 771–778
Shirai K, Ohmiya N, Taguchi A, Mabuchi N, Yatsuya H, Itoh A, Hirooka Y,
Niwa Y, Mori N, Goto H (2006) Interleukin-8 gene polymorphism
associated with susceptibility to non-cardia gastric carcinoma with
microsatellite instability. J Gastroenterol Hepatol 21: 1129–1135
Sterne JA, Egger M, Smith GD (2001) Systematic reviews in health care:
investigating and dealing with publication and other biases in meta-
analysis. BMJ 323: 101–105
Sugimoto M, Furuta T, Shirai N, Nakamura A, Xiao F, Kajimura M,
Sugimura H, Hishida A (2007) Different effects of polymorphisms of
tumor necrosis factor-alpha and interleukin-1 beta on development of
peptic ulcer and gastric cancer. J Gastroenterol Hepatol 22: 51–59
Torres MM, Acosta CP, Sicard DM, Groot de Restrepo H (2004) [Genetic
susceptibility and risk of gastric cancer in a human population of Cauca,
Colombia]. Biomedica 24: 153–162
Wang P, Xia HH, Zhang JY, Dai LP, Xu XQ, Wang KJ (2007) Association of
interleukin-1 gene polymorphisms with gastric cancer: a meta-analysis.
Int J Cancer 120: 552–562
Wu MS, Chen LT, Shun CT, Huang SP, Chiu HM, Wang HP, Lin MT, Cheng
AL, Lin JT (2004) Promoter polymorphisms of tumor necrosis factor-
alpha are associated with risk of gastric mucosa-associated lymphoid
tissue lymphoma. Int J Cancer 110: 695–700
Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HP, Lin
JT (2002) Tumor necrosis factor-alpha and interleukin-10 promoter
polymorphisms in Epstein–Barr virus-associated gastric carcinoma.
J Infect Dis 185: 106–109
Wu MS, Wu CY, Chen CJ, Lin MT, Shun CT, Lin JT (2003) Interleukin-10
genotypes associate with the risk of gastric carcinoma in Taiwanese
Chinese. Int J Cancer 104: 617–623
Zambon CF, Basso D, Navaglia F, Belluco C, Falda A, Fogar P, Greco E,
Gallo N, Rugge M, Di Mario F, Plebani M (2005) Pro- and anti-
inflammatory cytokines gene polymorphisms and Helicobacter pylori
infection: interactions influence outcome. Cytokine 29: 141–152
TNF polymorphisms and gastric cancer
F Gorouhi et al
1451
British Journal of Cancer (2008) 98(8), 1443–1451 & 2008 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s